Healthcare / BiotechnologyStockholm
$0.21
-0.01 (-5.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-41.6M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$183M
P/E
N/A
•EV/EBITDA
N/A
•ROE
921.0%
↑Gross Margin
100.0%
↑Debt/Equity
-3.79
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-1823.8%
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.3M · net income $-48.6M · FCF $-41.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.3M | $2.3M | $4.2M | $78000.00 | — |
| Net Income | $-48.6M | $-48.6M | $-39.2M | $-54.1M | $-66.2M |
| EBITDA | $-46.1M | $-46.1M | $-38.9M | $-53.5M | $-64.8M |
| EPS | -0.07 | -0.07 | -0.07 | -0.13 | -0.37 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating Margin | -2045.7% | -2045.7% | -935.9% | -73380.8% | — |
| Net Margin | -2128.1% | -2128.1% | -929.8% | -69337.2% | — |
| Balance Sheet | |||||
| Debt/Equity | -3.79 | -3.79 | -3.45 | — | — |
| Current Ratio | 0.84 | 0.84 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-41.6M | $-41.6M | $-40.7M | $-53.2M | $-73.1M |
| Returns | |||||
| ROE | 921.0% | 921.0% | 658.7% | -1234.8% | -1146.2% |
| Valuation | |||||
| P/B | — | — | — | 26.99 | 14.13 |
| Growth & Yield | |||||
| Revenue Growth | -45.9% | -45.9% | 5303.8% | — | — |
| EPS Growth | 0.0% | 0.0% | 45.9% | 64.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-45.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.07 → -0.07
Residual
-45.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.